Gungor, B.Yagci, F. C.Gursel, I.Gursel, M.2015-07-282015-07-282014-07http://hdl.handle.net/11693/12613Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon alpha (IFN alpha) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.EnglishCpg OdnType I InterferonVaccine AdjuvantDendritic CellsOligodeoxynucleotidesActivationInductionArticle10.4161/21624011.2014.9501662162-402X